Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.
1 other identifier
observational
90
1 country
2
Brief Summary
The aims of the presented study are as follows:
- 1.To evaluate the endothelial function and arterial stiffness in a large cohort of prevalent CKD patients by means of non-invasive applantion tonometry.
- 2.To evaluate the association between the serum levels of the representatives of the various classes of uremic toxins and markers of endothelial function and arterial stiffness.
- 3.To evaluate the association between markers of inflammation and oxidative stress and markers of endothelial function and arterial stiffness.
- 4.To evaluate the association between echocardiographic parameters and markers of arterial stiffness
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2004
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2012
CompletedFirst Submitted
Initial submission to the registry
April 13, 2012
CompletedFirst Posted
Study publicly available on registry
April 17, 2012
CompletedOctober 17, 2018
October 1, 2018
8 years
April 13, 2012
October 15, 2018
Conditions
Keywords
Study Arms (1)
CKD patients
Eligibility Criteria
CKD patients
You may qualify if:
- Age: 18-60
- Chronic kidney disease: according to the K-DOQI guidelines ( kidney damage ≥ three months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifest by either: pathological abnormalities; or markers of kidney damage, including damage in the composition of blood or urine test, or abnormalities in imaging tests; GFR\< 60 ml/min/1.73m² for ≥ three months, with or without kidney damage)
- Written informed consent
You may not qualify if:
- major illnesses( life expectancy of \< 1 year)
- history of atrial fibrillation
- history of myocardial infarction, unstable angina, congestive heart failure, peripheral vascular diasease ,cerebrovascular disease, diabetes
- (nonechogenic)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
University Hospitals
Leuven, 3000, Belgium
UZ Leuven
Leuven, 3000, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 13, 2012
First Posted
April 17, 2012
Study Start
January 1, 2004
Primary Completion
January 1, 2012
Study Completion
January 1, 2012
Last Updated
October 17, 2018
Record last verified: 2018-10